13 September 2021 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today published advice accepting three new medicines.

Selpercatinib (Retsevmo) was accepted for interim use subject to on-going evaluation and future reassessment for the treatment of rare, thyroid cancers with a specific type of genetic change.

Read SMC press release